SARS-CoV2 Infection Clinical Trial
Official title:
Clinical Agreement Study of 'TekiTrustTM SARS-CoV-2 Neutralizing Antibody Detection ELISA Kit' and 'TekiTrustTM SARS-CoV-2 Neutralizing Antibody Detection Rapid Test'
The purpose of this study is to determine if the TekiTrust Enzyme-Linked Immunosorbent Assay (ELISA) Kit and TekiTrust Rapid Test can accurately determine the amount of antibodies to fight the COVID-19 virus in sampled blood compared to the standard Plaque Reduction Neutralization Test (PRNT) test. When a person has COVID-19 they develop antibodies to the virus which are contained in their blood stream. After a certain period, the number of antibodies to fight (neutralize) the virus begin to decrease. One common way to measure the amount of antibodies in the blood is to use a test called the PRNT. The focus of this study is to compare the ability of the TekiTrust ELISA Kit and the TekiTrust Rapid Test with the PRNT to determine if these tests can measure the antibodies equally well.
Participants who have been previously diagnosed with COVID-19 within the past 3 months through any FDA emergency use approved (EUA) assay test will eligible for inclusion in the study. A blood and fingerstick sample will be obtained from the participant and for subjects with a positive test and symptom onset of less than 30 days a repeat RT-PCR nasal pharyngeal swab sample will be taken. The fingerstick sample will be used onsite by qualified site staff to test the TekiTrust SARS-CoV-2 Neutralizing Antibody Detection Rapid Test. These results will be compared to the whole blood sample sent to the lab which will be analysed for SARS CoV-2 neutralizing antibodies using the TekiTrust SARS-CoV-2 Neutralizing Antibody Detection ELISA Kit and the comparator Plaque Reduction Neutralization Test (PRNT) test. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
| Recruiting |
NCT05311410 -
Viral Kinetics of SARS-CoV-2 in Patients With COVID-19 in the Intensive Care Unit Undergoing Dental Procedures
|
N/A | |
| Active, not recruiting |
NCT05073718 -
SARS-CoV-2 and Acetylsalicylic Acid (SARA)
|
Phase 3 | |
| Completed |
NCT05055492 -
The School SPIT Study - Elementary Schools in High COVID-19 Incidence Regions
|
N/A | |
| Completed |
NCT05055505 -
The School SPIT Study - Elementary Schools in Low COVID-19 Incidence Regions
|
N/A | |
| Completed |
NCT05060510 -
The School SPIT Study - COVID-19 Testing in Secondary Schools
|
N/A | |
| Completed |
NCT05054218 -
COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients
|
||
| Completed |
NCT05449392 -
Topical Antibacterial Agents for Prevention of COVID-19
|
Phase 1 | |
| Completed |
NCT05076253 -
Efficacy of Ivermectin in COVID-19
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05172024 -
Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)
|
||
| Terminated |
NCT05593770 -
International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response
|
Phase 2/Phase 3 | |
| Completed |
NCT05030974 -
RECOVAC Repeated Vaccination Study
|
Phase 4 | |
| Withdrawn |
NCT05067946 -
Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT05013034 -
Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients
|
Phase 2 | |
| Withdrawn |
NCT05393999 -
SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations
|
Phase 2 | |
| Recruiting |
NCT05047783 -
Masitinib in Patients With Symptomatic Mild to Moderate COVID-19
|
Phase 2 | |
| Not yet recruiting |
NCT05116657 -
Obstructive Sleep Apnoea Post Covid 19: Role of the Upper Airway Microbiome
|
||
| Recruiting |
NCT04590222 -
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19
|
||
| Completed |
NCT04953039 -
Use of Saliva for COVID-19 Diagnosis
|
||
| Recruiting |
NCT04999098 -
Echinaforce COVID-19 Shedding Study
|
Phase 4 |